GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Net Income From Continuing Operations

Y-Biologics (XKRX:338840) Net Income From Continuing Operations : ₩-19,574 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Y-Biologics's net income from continuing operations for the three months ended in Mar. 2024 was ₩-1,624 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-19,574 Mil.

Y-Biologics Net Income From Continuing Operations Historical Data

The historical data trend for Y-Biologics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Net Income From Continuing Operations Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial -18,379.06 -11,196.97 -10,028.59 -17,070.89 -18,804.40

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only -2,920.76 -2,789.90 -540.09 -14,620.31 -1,623.87

Y-Biologics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-19,574 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Y-Biologics (XKRX:338840) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Net Income From Continuing Operations
Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Website
https://www.ybiologics.com
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines